Status
Conditions
Treatments
About
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
To be considered for enrollment into this study, each patient must meet all of the following Inclusion Criteria:
Patients who meet any of the following Exclusion Criteria at the Randomization Visit will not be enrolled into the study:
Primary purpose
Allocation
Interventional model
Masking
49 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal